Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizophrenic patients

Archivum Immunologiae et Therapiae Experimentalis

Volumn 49, Issue 6, 2001, Pages 439-445

  Kamińska, Teresa ^a   Wysocka, Alicja ^b   Marmurowska Michałowska, Halina ^b   Dubas Ślemp, Halina ^b   Kandefer Szerszeń, Martyna ^a  

^a MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Cytokine production; IFN ; IFN ; IL 10; IL 2; IL 4; IL 6; IL 8; Paranoid schizophrenia; TNF

Indexed keywords

ALPHA INTERFERON; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; BLOOD; CELL CULTURE; FEMALE; HUMAN; IMMUNOLOGY; LEUKOCYTE; MALE; METABOLISM; PARANOID SCHIZOPHRENIA;

ADOLESCENT; ADULT; CELLS, CULTURED; CYTOKINES; FEMALE; HUMANS; INTERFERON TYPE II; INTERFERON-ALPHA; INTERLEUKINS; LEUKOCYTES; MALE; SCHIZOPHRENIA, PARANOID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035752895     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. AKIYAMA K. (1999): Serum levels of soluble IL-2 receptor α, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration. Schizophr. Res., 37, 97-106.
2. th ed., DC, American Psychiatric Press, Washington.
3. BENDTZEN K. (1988): Inteleukin-1, interleukin-6 and tumor necrosis factor in infection, inflammation and immunity. Immunol. Lett., 19, 183-192.
4. BESSLER A., LEVENTAL Z., KARP L., MODAI I., DJALDETTI M. and WEIZMAN A. (1995): Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biol. Psychiatry, 38, 297-302.
5. CANTELL K., PULLKINEN E., ELOSNO R. and SUOMINEA J. (1980): Effect of interferon on severe psychiatric diseases. Ann. Clin. Res., 12, 131-132.
6. CAZZULLO C. L., SACCHETTI E., GALLUZZO A., PANARIELLO A., COLOMBO F., ZAGLIANI A. and CLERICI M. (2001): Cytokine profiles in drug-naive schizophrenic patients. Schizophr. Res., 47, 293-298.
7. CAZZULLO C. L., SCARONE S., GRASSI B., VISMARA C., TRABATTONI D., CLERICI M. and CLERICI M. (1998): Cytokine production in chronic schizophrenia patients with or without paranoid behavior. Prog. Neuropsychopharmacol. Biol. Psychiatry, 22, 947-957.
8. FARRAR J. D., SMITH J. D., MURPHY T. L., LEUNG S., STARK G. R. and MURPHY K. M. (2000): Selective loss of type I interferon-induced STAT4 activation caused by minisatellite insertion in mouse STAT2. Nat. Immunol., 1, 65-69.
9. GANGULI R., BRAR J. S., CHENGAPPA K. N. R., DELO M., YANG Z. W. and SHURIN G. (1995): Mitogen stimulated interleukin-2 production in newer-medicated, first-episode schizophrenic patients. Arch. Gen. Psychiatry, 52, 668-672.
10. GANGULI R., RABIN B. S. and BELLE S. H. (1989): Decreased interleukin-2 production in schizophrenic patients. Biol. Psychiatry, 26, 427-430.
11. GANGULI R., YANG Z., SHURIN G., CHENGAPPA K. N. R., BRAR J. S., GUBBI A. V. and RABIN B. S. (1994): Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res., 51, 1-10.
12. GATTAZ W. F., DALGALARRADO P. and SCHRÖDER H. C. (1992): Abnormalities in serum concentrations of interleukin-2, interferon α and interferon γ in schizophrenia not detected. Schizophr. Res., 6, 237-241.
13. GIMBRONE M. A., ORBIN M. S., BROCK A. F., LUIS E. A., HASS P. E., HEBERT C. A., YIP Y. K., LEUNG D. W., LOWE D. G., KOHR W. J., DARBONNE W. C., BECHTOL K. B. and BAKER J. B. (1989): Endothelial interleukin-8: A novel inhibitor of leukocyte-endothelial interactions. Science, 246, 1601-1603.
14. HAACK M., HINZE-SELCH D., FENZEL T., KRAUS T., KUHN M., SCHULD A. and POLLMÄCHER T. (1999): Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J. Psychiatric Res., 33, 407-418.
15. INGLOT A. D., LESZEK J., PIASECKI E. and SYPUŁA A. (1994): Interferon responses in schizophrenia and major depressive disorders. Biol. Psychiatry, 35, 464-473.
16. IV E. C. (2001): Interferons: potential roles in affect. Med. Hypotheses, 56, 558-566.
17. KAMMEN D. P., MCALLISTER-SISTILLI C. G., KELLEY M. E., GURKLIS J. A. and YAO J. K. (1999): Elevated interleukin-6 in schizophrenia. Psychiatr. Res., 87, 129-136.
18. KATILA H., APPELBERG B., HURME M. and RIMON R. (1994): Plasma levels of interleukin-1β and interleukin-6 in schizophrenia, other psychoses, and affective disorders. Schizophr. Res., 12, 29-34.
19. KAY S. R., OPLER L. A. and LINDENMAYER J. P. (1989): The positive and negative syndrome scale (PANSS); rationale and standarization. Br. J. Psychiatry, 155 (suppl. 7), 59-65.
20. KIM Y. K., KIM L. and LEE M. S. (2000): Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr. Res., 44, 165-167.
21. KIM Y. K., LEE M. S. and SUH K. Y. (1998): Decreased interleukin-2 production in Korean schizophrenic patients. Biol. Psychiatry, 43, 701-704.
22. KIRCHNER H., KLEINICKE C. and DIEGEL W. (1982): A whole blood technique for testing production of human interferon by leukocytes. Immunol. Methods, 48, 213-219.
23. KITCHING A. R., TIPPING P. G., TIMOSHANKO J. R. and HOLDSWORTH S. R. (2000): Endogenous interleukin-10 regulates Th1 responses that induce crescentic glomerulonephritis. Kidney Int., 57, 518-525.
24. KNIGHT J. G., KNIGHT A. and PERT C. B. (1987): Is schizophrenia a virally triggered antireceptor autoimmune disease? In HELMCHEN H. and HENN F. A. (eds.): Biological perspectives of schizophrenia. Willey, Chichester, 107-127.
25. LESZEK J., INGLOT A. D., CANTELL C. and WASIK A. (1991): Natural human leukocyte interferon in the treatment of schizophrenia. Eur. J. Psychiatry, 5, 55-63.
26. LIBIKOVA H., BREIER S., KOCISOVA M., POGADY J., STUNZNER D. and UJHAZOVA D. (1979): Assay of interferon and viral antibodies in cerebrospinal fluid in clinical neurology and psychiatry. Acta Biol. Med. Germ., 38, 879-893.
27. LICINIO J., SEIBYL J. P., ALTMUS M., CHARNEY D. S. and KRYSTAL J. H. (1993): Elevated cerebrospinal fluid levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am. J. Psychiatry, 150, 1408-1410.
28. LIN A., KENIS G., BIGNOTTI S., TURA G. J. B., DE JONG R., BOSMANS E., PIOLI R., ALTAMURA C., SCHARPE S. and MAES M. (1998): The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr. Res., 32, 9-15.
29. MAES M., BOSMANS E., CALABRESE J., SMITH R. and MELTZER H. Y. (1995): Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatr. Res., 29, 141-152.
30. MAES M., BOSMANS E., KENIS G., DE JONG R., SMITH R. S. and MELTZER H. Y. (1997): In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr. Res., 26, 221-225.
31. MAES M., BOSMANS E., RANJAN R., VANDOOLAEGHE E., MELTZER H. Y., DE LEY M., BERGHMANS R., STANS G. and DESNYDER R. (1996): Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. Schizophr. Res., 21, 39-50.
32. MAES M., DELANGHE J., RANJAN R., MELTZER H. Y., DESNYDER R., COOREMAN W. and SCHARPE S. (1997): The acute phase protein response in schizophrenia, mania and major depression: effects of psychotropic drugs. Psychiatry Res., 66, 1-11.
33. MAES M., MELTZER H. Y. and BOSMANS E. (1994): Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr. Scand., 89, 346-351.
34. MCALISTER C. G., VAN KAMMEN D. P., REHN T. J., MILLER A. L., GURKLIS J. and KELLEY M. E. (1995): Increases in CSF levels of IL-2 in schizophrenia: Effects of recurrence of psychosis and medical status. Am. J. Psychiatry, 152, 1291-1297.
35. MITTLEMAN B. B., CASTELLANOS F. X., JACOBSEN L. K., RAPOPORT J. L., SWEDO S. E. and SHEARER G, M. (1997): Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. J. Immunol., 159, 2994-2999.
36. MUKAIDA N., SHIROO M. and MATSUSHIMA K. (1989): Genomic structure of the human monocyte-derived neutrophil chemotactic factor IL-8. J. Immunol., 143, 1366-1371.
37. MÜLLER N., RIEDEL M., ACKENHEIL M. and SCHWARZ M. J. (1999): The role of immune function in schizophrenia: an overview. Eur. Arch. Psychiatry Clin. Neurosci., 249 (suppl. 4) IV/62-IV/68.
38. NAUDIN J., CAPO C., GIUSANO B., MEGE J. L. and AZORIN J. M. (1997): A differential role for interleukin-6 and tumor necrosis factor-α in schizophrenia? Schizophr. Res., 26, 227-233.
39. NAUDIN J., MEGE J. L., AZORIN J. M. and DASSA D. (1996): Elevated circulating levels of IL-6 in schizophrenia. Schizophr. Res., 20, 269-273.
40. O'SHEA J. J. and VISCONTI R. (2000): Type 1 IFNs and regulation of Th1 responses: enigmas both resolved and emerge. Nat. Immunol., 1, 17-19.
41. PREBLE O. T. and TORREY E. F. (1985): Serum interferon in patients with psychosis. Am. J. Psychiatry, 142, 1184-1186.
42. RAMCHAND R., WEI J., RAMCHAND C. N. and HEMMINGS G. P. (1994): Increased serum IgE in schizophrenic patients who responded poorly to neuroleptic treatment. Life Sci., 54, 1579-1584.
43. RIMON R. and AHOKAS A. (1987): Interferon in schizophrenia. In: KURSTAK W., LIPOWSKI P. V. and MOROZOV P. V.: Viruses, immunity and mental disorders. Plenum, New York, 379-382.
44. ROTHERMUNDT M., AROLT V., LEADBEATER J., PETERS M., RUDOLF S. and KIRCHNER H. (2000): Cytokine production in unmedicated and treated schizophrenic patients. Neuroreport, 22, 3385-3388.
45. ROTHERMUNDT M., AROLT V., WEITZSCH C., ECKHOFF D. and KIRCHNER H. (1998): Immunological dysfunction in schizophrenia: a systematic approach. Neuropsychobiology. 37, 186-193.
46. SCHATTNEK A., CORI Y., HAHN T. and SIROTA P. (1996): No evidence for autoimmunity in schizophrenia. J. Autoimmun., 9, 661-666.
47. SINIGAGLIA F., D'AMBROSIO D. and ROGGE L. (1999): Type I interferons and the Th1/Th2 paradigm. Dev. Comp. Immunol., 23, 657-663.
48. SIROTA P., SCHILD K., ELIZUR A., DJALDETTI M. and FISHMAN P. (1995): Increased interleukin-1 and interleukin-3 like activity in schizophrenia patients. Prog. Neuropsychopharmacol. Biol. Psychiatry, 19, 75-83.
49. THEODOROPOULU S., SPANAKOS G., BAXEVANIS C. N., ECONOMOU M., GRITZAPIS A. D., PAPAMICHAIL M. P. and STEFANIS C. N. (2001): Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients. Schizophr. Res., 15, 13-25.
50. VAN KAMMEN D. P., MCALLISTER-SISTILLI C. G. and KELLEY M. E. (1997): Relationship between immune and behavioral measures in schizophrenia. In WIESELMAN G. (ed.): Current update in psychoimmunology. Springer Verlag Wien, New York, 51-55.
51. WILKE I., AROLD V., ROTHERMUNDT M., WEITZSCH C., HORNBERG M. and KIRCHNER H. (1996): Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur. Arch. Psychiatry Clin. Neurosci., 246, 279-284.